169 related articles for article (PubMed ID: 36434292)
1. A standard dose of linezolid puts patients with hepatic impairment at risk of overexposure.
Liao R; Dong Y; Chen L; Wang T; Li H; Dong H
Eur J Clin Pharmacol; 2023 Jan; 79(1):149-157. PubMed ID: 36434292
[TBL] [Abstract][Full Text] [Related]
2. Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients.
Kawasuji H; Tsuji Y; Ogami C; Kimoto K; Ueno A; Miyajima Y; Kawago K; Sakamaki I; Yamamoto Y
BMC Pharmacol Toxicol; 2021 Mar; 22(1):13. PubMed ID: 33663616
[TBL] [Abstract][Full Text] [Related]
3. A 10-Year Experience of Therapeutic Drug Monitoring (TDM) of Linezolid in a Hospital-wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting TDM in the Majority of Patients?
Pea F; Cojutti PG; Baraldo M
Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):303-308. PubMed ID: 28419737
[TBL] [Abstract][Full Text] [Related]
4. Linezolid-induced thrombocytopenia increases mortality risk in intensive care unit patients, a 10 year retrospective study.
Kim HS; Lee E; Cho YJ; Lee YJ; Rhie SJ
J Clin Pharm Ther; 2019 Feb; 44(1):84-90. PubMed ID: 30243033
[TBL] [Abstract][Full Text] [Related]
5. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients.
Matsumoto K; Shigemi A; Takeshita A; Watanabe E; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y
Int J Antimicrob Agents; 2014 Sep; 44(3):242-7. PubMed ID: 25108880
[TBL] [Abstract][Full Text] [Related]
6. Reappraisal of Linezolid Dosing in Renal Impairment To Improve Safety.
Crass RL; Cojutti PG; Pai MP; Pea F
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31109977
[TBL] [Abstract][Full Text] [Related]
7. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia.
Nukui Y; Hatakeyama S; Okamoto K; Yamamoto T; Hisaka A; Suzuki H; Yata N; Yotsuyanagi H; Moriya K
J Antimicrob Chemother; 2013 Sep; 68(9):2128-33. PubMed ID: 23625638
[TBL] [Abstract][Full Text] [Related]
8. Estimation of linezolid exposure in patients with hepatic impairment using machine learning based on a population pharmacokinetic model.
Liao R; Chen L; Cheng X; Li H; Wang T; Dong Y; Dong H
Eur J Clin Pharmacol; 2024 Aug; 80(8):1241-1251. PubMed ID: 38717625
[TBL] [Abstract][Full Text] [Related]
9. Linezolid-Induced Thrombocytopenia in Patients with Renal Impairment: A Case Series, Review and Dose Advice.
Laarhuis SRE; Kerskes CHM; Nijziel MR; van Wensen RJA; Touw DJ
Drugs R D; 2024 Mar; 24(1):109-115. PubMed ID: 38480595
[TBL] [Abstract][Full Text] [Related]
10. Risk factor analysis for linezolid-associated thrombocytopenia in critically ill patients.
Cazavet J; Bounes FV; Ruiz S; Seguin T; Crognier L; Rouget A; Fourcade O; Minville V; Conil JM; Georges B
Eur J Clin Microbiol Infect Dis; 2020 Mar; 39(3):527-538. PubMed ID: 31853741
[TBL] [Abstract][Full Text] [Related]
11. Proactive therapeutic drug monitoring (TDM) may be helpful in managing long-term treatment with linezolid safely: findings from a monocentric, prospective, open-label, interventional study.
Cojutti PG; Merelli M; Bassetti M; Pea F
J Antimicrob Chemother; 2019 Dec; 74(12):3588-3595. PubMed ID: 31504570
[TBL] [Abstract][Full Text] [Related]
12. Establishment and validation of a risk prediction model incorporating concentrations of linezolid and its metabolite PNU142300 for linezolid-induced thrombocytopenia.
Xu J; Lu J; Yuan Y; Duan L; Shi L; Chen F; Cao Y; Xu G; Feng Z; Li L; Xue H; Sun J; Zhou Q; Zhuang Z; Tang L
J Antimicrob Chemother; 2023 Aug; 78(8):1974-1981. PubMed ID: 37341139
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the risk factors of linezolid-related haematological toxicity in Chinese patients.
Dai Y; Jiang S; Chen X; Han L; Zhang C; Yu X; Zhang X
J Clin Pharm Ther; 2021 Jun; 46(3):807-813. PubMed ID: 33555057
[TBL] [Abstract][Full Text] [Related]
14. Initially Reduced Linezolid Dosing Regimen to Prevent Thrombocytopenia in Hemodialysis Patients.
Kawasuji H; Tsuji Y; Ogami C; Kaneda M; Murai Y; Kimoto K; Ueno A; Miyajima Y; Fukui Y; Sakamaki I; Yamamoto Y
Antibiotics (Basel); 2021 Apr; 10(5):. PubMed ID: 33925912
[TBL] [Abstract][Full Text] [Related]
15. Indocyanine green clearance test as a predictor of linezolid overexposure in septic patients.
Xu Y; Qu C; Yan M; Gu Q; Liu N
Int J Antimicrob Agents; 2023 Dec; 62(6):107006. PubMed ID: 37839718
[TBL] [Abstract][Full Text] [Related]
16. Association of clinical factors with thrombocytopenia in patients receiving linezolid treatment: a retrospective study.
Thi Phuong Thao L; Duc Trung N; Thi My L; Minh Hong L; Viet Hoan B; Quang Hung V; Dang Hai P
J Infect Dev Ctries; 2024 Feb; 18(2):285-290. PubMed ID: 38484357
[TBL] [Abstract][Full Text] [Related]
17. Dose optimisation of linezolid in critically ill patients based on a population pharmacokinetic model: A two-centre prospective interventional study.
Shi L; Zhang Y; Duan L; Huang L; Li J; Lu J; Zhuang Z; Yuan Y; Feng Z; Sun J; Liu X; Zhou Q; Xue H; Xu J; Tang L
Int J Antimicrob Agents; 2023 Aug; 62(2):106881. PubMed ID: 37301313
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and risk factors for severe linezolid-associated thrombocytopenia in pediatric patients: An analysis of a public database.
Yang S; Guo W; Chen M; Hu J; Feng N; Ju M; Qian Y
Medicine (Baltimore); 2023 Jun; 102(24):e34059. PubMed ID: 37327288
[TBL] [Abstract][Full Text] [Related]
19. High frequency of thrombocytopenia in patients with acute-on-chronic liver failure treated with linezolid.
Zhang YM; Yu W; Zhou N; Li JZ; Xu LC; Xie ZY; Lu YF; Li LJ
Hepatobiliary Pancreat Dis Int; 2015 Jun; 14(3):287-92. PubMed ID: 26063030
[TBL] [Abstract][Full Text] [Related]
20. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy.
Niwa T; Suzuki A; Sakakibara S; Kasahara S; Yasuda M; Fukao A; Matsuura K; Goto C; Murakami N; Itoh Y
Clin Ther; 2009 Oct; 31(10):2126-33. PubMed ID: 19922883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
